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The esophageal mucosa is among the sites colonized by human microbiota, the complex microbial ecosystem that
colonizes various body surfaces and is increasingly recognized to play roles in several physiological and pathological
processes. Our understanding of the composition of the esophageal microbiota in health and disease is challenged by
the need for invasive sampling procedures and by the dynamic nature of the esophageal environment and remains
limited in comparisonwith the information available for other body sites.Members of the genus Streptococcus appear
tobe themajor components of themicrobiota of thehealthy esophagus, although thepresenceof several other taxahas
also been reported.Dysbiosis, consisting of enrichment in someGram-negative taxa (includingVeillonella,Prevotella,
Haemophilus,Neisseria,Campylobacter, and Fusobacterium), has been reported in associationwith gastroesophageal
reflux disease and is hypothesized to contribute to the evolution of this condition toward Barrett’s esophagus (which
is themost common esophageal precancerous lesion) and, eventually, adenocarcinoma. SomeCampylobacter species
(mostly C. concisus) are also putatively involved in the progression of disease toward adenocarcinoma. However,
variable findings have recently been reported in additional studies. Causative relationships between dysbiosis or
specific bacterial species and esophageal diseases remain controversial and warrant further investigations.
Keywords: esophageal diseases; microbiota; esophagitis; Barrett’s esophagus; esophageal adenocarcinoma; esophageal
squamous cell carcinoma
Introduction
The human body has symbiotic relationships with
a complex and diverse array of microbial commu-
nities at various nonsterile body sites, which overall
constitute the human microbiota (HM). The sites
colonized by the HM include skin and various
mucousmembranes (e.g.,mouth, upper respiratory
tract, lower genitourinary tract, gastrointestinal
tract). The composition of the HM exhibits a
remarkable variability at various sites, among differ-
ent individuals, and at different times, depending on
several factors that are only partially understood.1–3
Until recently, knowledge of the HM com-
position was largely hampered by the limited
resolution allowed by cultural methods, which
cannot recover a large number of components of the
HM. The advent of culture-independent metage-
nomic methods capable of also characterizing the
nonculturable fraction of complex microbial com-
munities, in combination with high-throughput
next-generation sequencing (NGS) technologies,
has provided a fundamental breakthrough in
studying the composition of the HM.4–6
The HM is now considered an additional appara-
tus of the human body, capable of modulating sev-
eral developmental, metabolic, and immunological
pathways and playing a fundamental role in defense
against colonization by microbial pathogens.1,7–10
It is also clear that HM alterations (a condition
termed dysbiosis) can be associated with disease.11
The most paradigmatic example is represented by
the association between dysbiosis of the intestinal
microbiota, promoted by antibiotic treatments, and
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Clostridium difficile infection (CDI),12–14 which is
the leading cause of diarrhea among hospitalized
patients and has become a major public health
issue in several settings.15 Under these circum-
stances, the conventional treatment of CDI, based
on antibiotics active against C. difficile, may sus-
tain a vicious cycle wherein the dysbiotic status per-
sists and favors recurrences of CDI. In this context,
reconstitution of the intestinal microbiota by fecal
microbiota transplantation has proved extremely
successful and has definitively confirmed the role
of dysbiosis in the pathogenesis of CDI.16–18 An
association with altered composition of the HM
has now also been reported for several other dis-
eases, including inflammatory bowel diseases,19 col-
orectal cancer,20 obesity,21 diabetes,22 nonalcoholic
steatohepatitis,23 bacterial vaginosis,24 atopic der-
matitis, and psoriasis,9,25 although in these cases
a causative relationship remains to be definitively
established.
The esophageal mucosa is one of the sites colo-
nized by HM, and consequently there is an interest
in understanding a possible role of HM alterations
in esophageal diseases. Some articles have recently
reviewed various aspects of this topic.26–31 Here, we
provide an updated review of current knowledge on
the esophageal microbiota in health and in different
esophageal diseases anddiscuss themajor challenges
encountered in investigation of this topic.
The healthy esophagus and its microbiota
Structure and physiology of the healthy
esophagus
The esophagus is a muscular conduit of approxi-
mately 20–27 cm in length, with an internal mucosa
carrying a stratified squamous epithelial layer. It
plays the fundamental role of transferring the ali-
mentary bolus from the pharynx to the stomach.
At its distal end, a complex valve mechanism allows
passage of the bolus into the stomach and restricts
reflux of the gastric contents back into the esopha-
gus. The esophagus has a virtual narrow cavity that
is empty and collapsed, except during swallowing.
The epithelial layer of the esophagealmucosa is nor-
mally wet with saliva for the whole length and, as a
result, the pH is usually around 7. However, reflux
of gastric material may occur and cause a sudden
lowering of pH values (down to 2). This is mostly
limited to the distal third of the organ, and, nor-
mally, acidification is rapidly buffered by esophageal
motility. The potentially harmful effect of reflux on
the esophageal mucosa depends on the composi-
tion of the refluxate (commonly gastric acid and
ingesta, less frequently bile and pancreatic enzymes)
and the time of contact. In addition to mucosal
damage, reflux is capable of inducingmicroenviron-
mental variations. Therefore, whereas the environ-
ment of the proximal esophageal mucosa is similar
to the oral one, an environment that is intermediate
between the oral-like one of the proximal esophagus
and the gastric one has to be expected in the distal
esophageal mucosa.
The microbiota of the healthy esophagus
The esophageal mucosa hosts a resident micro-
biota, although in a smaller population as compared
with other districts of the gastrointestinal tract. In
fact, the HM of the gastrointestinal tract exhibits
substantial qualitative and quantitative differences,
with populations ranging from 10 cells per g/mL
of sampled material in the esophagus and stomach
to 1012 per g/mL of sampled material in the large
intestine.32,33
Considering the anatomic structure and function,
it was originally unclear whether the esophagus was
associated with a definedmicrobiota. The first stud-
ies on the esophageal microbiota, dating back to the
early 1980s and based on cultural methods, demon-
strated that the esophagus was not a sterile site and
did not simply contain a transient microbial popu-
lation originating from the oral cavity by swallow-
ing or from the stomach by gastroesophageal reflux
(GER).34–36 Consistently, it was later observed that
bacteria were closely associated with the esophageal
mucosal surface, confirming the presence of a resi-
dent microbiota at this site.37 More recently, knowl-
edge regarding the composition of the microbiota
of healthy individuals has been expanded through
the use of investigations based on metagenomic
approaches.4–6 However, the difficulties in obtain-
ing samples at this body site, compared with other
sites, have limited the number of studies on the
esophageal microbiota.
Few studies have focused on the composition
of the microbiota of the normal esophagus alone
(Table 1),37–40 but additional information has come
from studies investigating the esophageal micro-
biota in disease and including healthy patients as
controls for comparison (Tables 26,41–47 and 348–50).
The available information on the microbiota of the
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Table 1. Studies reporting the characterization of esophageal microbiota in the healthy individuals
Year
No. of
studied
subjects
Exclusion
criteria Method Samples
Sampled
esophageal
tract Main findings Reference
1998 20 Esophageal abnormalities Culture-based Aspirate Middle third Streptococcus, Enterococcus,
Staphylococcus, Klebsiella
38
2004 4 Recent antibiotic use
Previous gastric/
esophageal surgery
Active oral cavity infection
Culture-independent
(sequencing of 16S rRNA
gene clones, 25–30 clones/
sample analyzed)
Biopsy 2 cm above the
squamocolumnar
junction
Streptococcus, Prevotella,
Veillonella
37
2012 15 Esophageal abnormalities
Increased risk for endoscopic
complications
Culture-independent (NGS,
V2–V3 region of 16S rRNA
genes)
Biopsy and
esophageal
string test
Mid to distal Streptococcus, Prevotella,
Veillonella
39
2013 40 Age<20 or>75 years
Recent use of antibiotics or
PPIs
Gastroesophageal diseases
Ongoing infections
Culture-based Biopsy and
brush
5 cm below the upper
esophageal sphincter,
2 cm above the
squamocolumnar
junction
Streptococcus, Neisseria,
Haemophilus, Prevotella
40
NGS, next-generation sequencing; PPIs, proton pump inhibitors.
healthy esophageal mucosa, in terms of prevalence
and proportions of bacterial taxa, is summarized
in Figure 1 and briefly discussed below, with the
caveat that different methodological approaches,
differences in the sampled areas within the esoph-
agus, and the heterogeneity of inclusion/exclusion
criteria used in the various studies do not allow
fine-tuned comparisons and make it difficult to
reach a consensus on the comprehensivemicrobiota
composition of the healthy esophagus.
The presence of Streptococcus spp. was constantly
reported, and in high proportions, by all studies:
therefore, members of this genus appear to be a
dominant taxon in the microbiota of the normal
esophagus. Other bacterial genera frequently
detected (at least in half of the studies) in associ-
ation with streptococci, although usually in lower
proportions, include Prevotella, Fusobacterium,
and Veillonella. The presence of other genera (e.g.,
Haemophilus, Neisseria, Gemella, Granulicatella,
Lactobacillus, Actinomyces, Staphylococcus, Bac-
teroides, and Porphyromonas) was less frequently
reported, and some genera were only reported by
single studies (Fig. 1).
Notably, the prevalence of Streptococcus, Fusobac-
terium, Veillonella, and Prevotella has consis-
tently been reported in several studies based on
either culture-dependent or culture-independent
approaches and also on different specimens (biop-
sies, brushes, aspirates) (Tables 1–3), thus provid-
ing a strong indication of their contribution to the
composition of the core microbiota that colonizes
the healthy esophageal mucosa. The dominance of
streptococci and the frequent presence of other taxa
typical of the oropharyngeal microbiota have been
related to the composition of the microbial com-
munities of the oropharyngeal cavity, where a high
prevalence of streptococci is found, together with
Veillonella, Fusobacterium, Gemella, Granulicatella,
and Rothia,51,52 and have supported the notion that
the esophageal microbiota is primarily of oral ori-
gin. However, not all oral bacteria are apparently
able to colonize the esophageal mucosa, while sev-
eral members of the esophageal microbiota are not
present or are underrepresented in the oral cavity,
pointing to a diverse microbiota adaptation in the
two body sites.37,39,40,49
Major esophageal diseases
The environment of the esophagus and its patho-
logic states are closely connected. There is no doubt
that, apart from esophageal squamous cell can-
cer (ESCC), whose pathogenesis remains largely
unknown (although related to cigarette smoking
and alcohol consumption), all the most important
esophageal diseases are associated with GER and
GER-related environmental changes. These are rep-
resented by gastroesophageal reflux disease (GERD)
with or without esophagitis, Barrett’s esophagus
(BE), and esophageal adenocarcinoma (EAC), with
GERD generally representing the first step in the
evolution of disease toward BE and EAC.
TheprevalenceofGERDhasbeen rapidly increas-
ing in Western countries, where 20% of adults
today may be affected by this disease.53,54 The pres-
ence of short-duration reflux episodes is considered
physiologic, but GERD occurs when reflux becomes
symptomatic and/or causes esophageal mucosal
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Table 2. Studies reporting the characterization of esophageal microbiota in major esophageal diseases (E, BE, EAC,
ESCC)
Year
No. of
studied
subjects
Disease
group
(No.)
Control
group
(No.)
Exclusion
criteria Method Samples
Sampled
esophageal
tract Main findings Reference
1981 79 EC (79) – – Culture-based Aspirate – Detected bacteria
included
Bacteroidetes (39%),
Streptococcus (10%),
and coliforms (8%)
34
1982 12 EAC (7)
ESCC (5)
– – Culture-based Biopsy Proximal resection line
after cancer excision
Streptococcus and
Bacteroidetesmost
prevalent taxa
35
1983 101 EC (50) NE (51) Use of antibiotics Culture-based Aspirate – No differences in the
presence/absence of
specific taxa in EC vs.
controls.
Streptococcus and
Peptococcus the most
prevalent taxa
36
2004 20 EC (20) – – Culture independent
(sequencing of 16S
rRNA gene clones of
most members of the
oral microbiota,
except Neisseria,>10
clones/sample
analyzed)
Biopsy Cancerous and
noncancerous tissues
from each patient
Treponema denticola,
Streptococcus mitis,
and Streptococcus
anginosus prevalent
in both cancerous
and noncancerous
tissues and suggested
to have roles in
carcinogenic process
68
2005 24 E (12)
BE (3)
NE (9) Recent antibiotic use
Previous gastric/
esophageal surgery
Active oral cavity
infection
Culture independent
(sequencing of 16S
rRNA gene clones,
two clones/sample
analyzed)
Biopsy 2 cm above the
squamocolumnar
junction (NE and E),
2 cm above the
gastroesophageal
junction (BE)
Proof-of-concept study
demonstrating the
presence of a
nontransient
microbiota in the
reflux-exposed
esophageal mucosa
and the importance
of culture-
independent
approaches
41
2007 14 BE (7) NE (6)
E (1)
Recent antibiotic use Culture-based Biopsy and
aspirate
Middle to distal High-level colonization
by Campylobacter
(mostly C. concisus)
in BE, absence in
controls
42
2009 34 E (12)
BE (10)
NE (12) Recent antibiotic use
Previous gastric/
esophageal surgery
Active oral cavity
infection
HIV infection
Culture-independent
(sequencing of 16S
rRNA gene clones,
200 clones/sample
analyzed)
Biopsy 2 cm above the
squamocolumnar
junction
Type I microbiota
(dominated by
Gram-positive taxa
of the phylum
Firmicutes) in
normal esophagus,
type II microbiota
(enriched in
Gram-negative taxa)
in E and BE
43
2013 18 E (6)
BE (6)
NE (6) Recent use of
antibiotics or PPIs
Gastric/esophageal
surgery
Active oral cavity
infection
HIV, HBV, or HCV
infection
Culture-independent
(sequencing of 16S
rRNA gene clones,
about 24
clones/sample
analyzed)
Biopsy 1 cm above the
gastroesophageal
junction
Enrichment of
Prevotella,
Fusobacterium,
Veillonella, and
Neisseria in BE
44
2013 34 E (8)
BE (8)
EAC (10)
NE (8) Recent use of
antibiotics or PPIs
Culture-based plus
qRT-PCR for
detection of specific
taxa in a larger
cohort
Biopsy 5 cm above the
esophagogastric
junction, or at the
upper limit of BE or
at site of pathology
Campylobacter (mostly
C. concisus)
expansion in E and
BE compared to AD
and controls
(suggested to be
specific to
reflux-exposed
mucosa)
45
2014 34 E (13)
BE (6)
NE in
GERD (15)
Recent use of
antibiotics or PPIs
Culture-independent
(NGS, V6–V7 region
of 16S rRNA genes)
Biopsy Normal-appearing
mucosa above the
inflammation site or
BE
No significant
difference between
microbiota of normal
and abnormal
esophagus. Relevant
effect of PPI
treatment
46
Continued
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Table 2. Continued
Year
No. of
studied
subjects
Disease
group
(No.)
Control
group
(No.)
Exclusion
criteria Method Samples
Sampled
esophageal
tract Main findings Reference
2015 12 BE (12) – EAC Culture-independent
(NGS, V3–V4 region
of 16S rRNA genes)
Biopsy and brush Normal-appearing and
BE mucosa
Streptococcus and
Prevotella dominant
species. No
substantial
intraindividual
difference between
squamous and BE
mucosal microbiota
59
2016 26a BE (13)
EAC (5)
NE in
GERD (8)
– Culture-independent
(PCR–ESI–MS-TOF)
Biopsy In some cases, both
normal and diseased
mucosa
Higher prevalence of
Streptococcus
pneumoniae in
GERD and BE,
compared to EAC
47
–, absent or not specified.
aThe authors reported 28 patients, which possibly included two patients with dysplasia, in addition to those indicated in the table.
E, reflux-related esophagitis; EC, esophageal carcinoma (not further specified); EAC, esophageal adenocarcinoma; ESCC, esophageal
squamous cell carcinoma; GERD, gastroesophageal reflux disease; NE, normal esophagus; BE, Barrett’s esophagus; NGS, next-
generation sequencing; PCR–ESI–MS-TOF, PCR-based electron spray ionization–time-of-flight mass spectrometry; PPIs, proton
pump inhibitors; qRT-PCR, quantitative real-time PCR.
damage associated with inflammation (esophagi-
tis). This seems to be attributable to an increased
GER/mucosa contact time, which overwhelms the
protective mechanisms of the esophageal mucosa,
including esophageal clearing, salivation, bicarbon-
ate secretion by esophageal submucosal glands,
and the histologic/functional endothelial config-
uration. Salivation may play a major role in
the protective effect of esophageal mucosa.55 In
fact, it does not appear incidental that esophagi-
tis, BE, and EAC are generally limited to the
lower third of the esophagus, where the saliva-
tion effect is lower and the environment is inter-
mediate between the esophageal and the gastric
environments.
Although the role of the individual components
of GER has been debated,56 there is no doubt that
chronic exposure to reflux may determine the onset
of esophagitis and its progression, although not
frequently, to BE and EAC. BE is represented by the
replacement of the stratified squamous epithelium
of the distal esophagus with an intestinal columnar
metaplastic epithelium. It is the most common
esophageal precancerous lesion and an intermediate
step in the sequence GER–esophagitis–intestinal
metaplasia–dysplasia–EAC. EAC, therefore, like
colon cancer, identifies a multistep cancer model
that is being thoroughly studied. The evolution
of the sequence has been shown to largely depend
upon inflammation and its mediators, such as
cyclooxygenase-2 (COX-2).57 However, although
mucosal inflammation can be directly caused
by GER, it could also be caused by esophageal
microbiome variations induced byGER (see below).
The microbiota in diseased esophagus
and its potential role in diseases
Microbiota in GERD, BE, and esophageal
cancers
As previously mentioned, GERD-related esophagi-
tis and Barrett’s metaplasia are themajor conditions
associated with chronic reflux of acidic material
from the stomach into the lower part of the esoph-
agus. Under these circumstances, a modification
of the esophageal microbiota is expected to occur
owing to the altered environment, and it has been
hypothesized that the modification of the micro-
biota could contribute to disease persistence and/or
progression.26–31 The relevant literature available on
this subject is summarized in Table 2 and discussed
below.
A positive association between the load of bac-
terial colonization and severity was first reported
in 2004 by a study based on Gram staining of
esophageal biopsies in reflux-related esophagitis and
BE.58 Shortly thereafter, Pei et al.41 demonstrated the
presence of a nontransient microbial population in
GER-exposed esophageal mucosa and, at the same
time, established the importance and feasibility of
culture-independent approaches for investigating
the complexity of the esophageal microbiota.
A subsequent culture-based characterization of
microbial communities in patients affected by BE
compared to controls was carried out byMacfarlane
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Table 3. Studies reporting thecharacterizationofesophagealmicrobiotaassociatedwithsomeuncommonesophageal
diseases
Year
No. of
studied
subjects
Disease
group
(No.)
Control
group
(No.)
Exclusion
criteria Method Samples
Sampled
esophageal
tract Main findings Reference
2002 25 CME (15) NE (10) Grade IV megaesophagus
Recent antibiotic use
GERD (for controls)
Culture-based Aspirate Distal Higher bacterial load
and greater
variability in CME
(e.g., enrichment in
Veillonella)
compared to controls
48
2015 68 EoE (35) NE and
mild
non-EoE
(33)
Use of antibiotics or oral
steroids
Immune or other
inflammatory GI disorders
Culture-independent
(NGS, V1–V2 region
of 16S rRNA genes)
Biopsy Distal Enrichment in
Proteobacteria
(Neisseria and
Corynebacterium)
and decrease of
Firmicutes
(Streptococcus and
Atopobium) in EoE
49
2015 70 EoE (37)
E (8)
NE (25) Age<7 years
Esophageal abnormalities
Antibiotic use
Increased risk for endoscopic
complications
Culture-independent
(NGS, V1–V2 region
of 16S rRNA genes)
Esophageal string
test
Middle to distal Enrichment in
Proteobacteria
(Haemophilus) and
decrease of
Firmicutes in active
EoE
50
CME, chagasic megaesophagus; E, reflux-related esophagitis; EoE, eosinophilic esophagitis; GI, gastrointestinal; NE, normal esoph-
agus; NGS, next-generation sequencing; GERD, gastroesophageal reflux disease.
et al.42 In that study, although microbial growth
was observed only from a small subset of samples
(i.e., four and three samples from BE and controls,
respectively), the authors observed a uniquely high
level of colonization byCampylobacter spp. (namely
C. concisus and C. rectus) in BE and hypothesized a
potential role of this pathogen indisease progression
to EAC.
In 2009, following a large-scale, culture-
independent study (i.e., 6800 16S bacterial rRNA
gene clones sequenced from 34 individuals), Yang
et al.43 first identified two distinct patterns of
esophageal microbiota associated with normal
and abnormal esophageal mucosa. In particular, a
microbiota dominated by Gram-positive taxa of the
Streptococcus genus (phylum Firmicutes), named
type I microbiota, was found to characterize the
normal esophageal mucosa, while a shift toward a
microbiota enriched in Gram-negative taxa (e.g.,
Veillonella, phylum Firmicutes; Prevotella, phylum
Bacteroidetes; Haemophilus, Neisseria, and Campy-
lobacter, phylum Proteobacteria; Fusobacterium,
phylum Fusobacteria), named type II microbiota,
was found to be associated with the esophageal
mucosa in cases of GERD-related esophagitis
and BE. The presence of distinct microbiota
compositions in normal esophagus, GERD-related
esophagitis, and BE was also confirmed in a sub-
sequent study, performed with a similar approach,
although with a lower discrimination power (i.e.,
424 bacterial 16S rRNA gene clones sequenced
from 18 individuals).44 Indeed, in that study, Liu
et al. observed that, compared with healthy con-
trols, the esophageal microbiota in GERD-related
esophagitis and BE was enriched in Prevotella
(phylum Bacteroidetes) and Fusobacterium (phy-
lum Fusobacteria), and showed differences in the
relative abundance of Firmicutes (a decrease of
Streptococcus and an enrichment in Veillonella,
mostly in BE) and of Proteobacteria (an overall
decrease, but with enrichment in Neisseria).44
On the other hand, the first study that used
NGS technologies for characterization of the
esophageal microbiota failed to detect significant
differences between patients with normal mucosa
and patients with reflux-related esophagitis or
BE.46 These authors hypothesized that the lack of
identification of the previously described type I
and type II esophageal microbiota in healthy and
diseased esophagus could be due to issues related
to the experimental design and the methodological
approach (e.g., in this study, all controls had
GERD symptoms, and samples were obtained
from normal-appearing mucosa above the diseased
tissue,46 while in the study by Yang et al.,43 only one-
third of controls hadGERD symptoms, and samples
were obtained from diseased mucosa). Moreover,
this study first demonstrated a remarkable effect
of proton pump inhibitor (PPI) treatment on
the microbiota composition in the esophageal
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Figure 1. Overview of the frequency and relative abundance of bacterial taxa (at the genus level) associated with the healthy
esophageal mucosa reported by studies investigating the composition of the esophageal microbiota in healthy individuals. The
presence of each bacterial genus is indicated by a circle whose size and color indicate the relative abundance: black-filled larger
circles represent bacterial genera with a relative abundance20%, gray-filled intermediate circles represent genera with a relative
abundance 10% and <20%, and white-filled smaller circles represent genera with a relative abundance 1% and <10%. For
Ref. 49, the reported frequencies were calculated on rarefied OTUs provided as supplemental material. Bacterial genera with an
abundance<1% and cases where classification at the genus level was not available (e.g., the unidentified oral bacteria in Ref. 41)
are not reported. Clustering of genera in different phyla are also shown. For Ref. 46, data at the genus level were not available, and
the predominant phyla are indicated by striped boxes.When data for different types of esophageal specimens were available (e.g., in
Refs. 39, 42, and 40), only those related to biopsy specimens were considered and included for comparison. For Ref. 40, the reported
data refer to lower esophageal samples.
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mucosa. In particular, PPI treatment was found
to be associated with an enrichment in several
members of the phylum Firmicutes (e.g., Clostridi-
aceae and Lachnospiraceae) and with a decrease
in members of the phylum Proteobacteria (e.g.,
Comamonadaceae). Since, in the study by Yang
et al.,43 the information on PPI treatment was not
available, it is possible that some of the observed
shifts might be associated with PPI treatment, and
this could represent an additional factor contribut-
ing to the lack of consistency in the results of the two
studies.
More recently, Gall et al.59 observed that Strep-
tococcus and Prevotella dominated the esophageal
microbiota of a cohort of BE patients, with no sub-
stantial intraindividual differences between normal
and metaplastic esophageal mucosa. In that study,
the authors also pointed out that the Streptococcus
to Prevotella ratio was significantly associated with
some important risk factors for BE and EAC (e.g.,
waist-to-hip ratio, hiatal hernia length) and encour-
aged further studies to investigate the clinical signif-
icance of this finding.
The microbiota composition in esophageal can-
cers has been investigated since the early 1980s,34
and during the last three decades it has been stud-
ied using diverse culture-dependent and culture-
independent approaches (Table 2). The interest in
such studies arises from the recognition that gas-
trointestinal tract dysbiosis may play a role in dis-
ease initiation and perpetuation.20,26–31,60–62 The
mechanisms accounting for dysbiosis-mediated car-
cinogenesis could involve both the induction of a
cancer-promoting inflammatory response (mainly
mediated by innate immunity) and the produc-
tion of procarcinogenic compounds by the bac-
terial taxa enriched in dysbiosis.20,26,28–31,60,61,63 In
fact, innate immunity receptors, such as Toll-
like receptors and Nod-like receptors, are major
effectors in the maintenance of the gastrointesti-
nal microbiota equilibrium, and their activation
in the presence of dysbiosis has been demon-
strated to trigger an inflammatory response pro-
moting carcinogenesis.20,26,28–31,60,61 Inflammation,
in turn, is known to contribute to dysbiosis by
several still incompletely understood mechanisms
(e.g., inflammation-derived increased availability
of nitrates may promote enrichment of facultative
anaerobes, such as Enterobacteriaceae, which are
able to use nitrates as electron acceptors), giving
rise to the vicious cycle of dysbiosis–inflammation–
dysbiosis.20,26,28–31,60,61 Besides the activation of
innate immunity and the possible direct proinflam-
matory potential, certain bacteria are also capable of
modulating carcinogenesis through the production
of genotoxic compounds (e.g., cytolethal distend-
ing toxin and colibactin, produced by members of
Enterobacteriaceae, Campylobacter spp., and Heli-
cobacter spp.)8,64,65 or other procarcinogenic
metabolites (e.g., superoxide and hydrogen sul-
fide, produced by Enterococcus faecalis and Fusobac-
terium, respectively).66,67
The earlier studies on the correlation between
microbiota and esophageal cancers suffered from
the intrinsic limitations of culture-dependent
approaches, the absence of control groups, and/or
the lack of histological differentiation between
ESCC and EAC, which are known to have dis-
tinct risk profiles (Table 2).34–36 In 2004, Narikiyo
et al.68 first used a culture-independent approach
for the characterization of the microbiota in
esophageal cancers, even though it is not clear if the
study included ESCC, EAC, or both. In particular,
Narikiyo et al. characterized the microbiota of nor-
mal and cancerous esophageal tissue in 20 patients
undergoing surgery for esophageal carcinoma and
observed that both were consistently dominated by
Treponema denticola and streptococci, including S.
mitis and S. anginosus. On the basis of the detec-
tion of those three species in a number of addi-
tional biopsies of esophageal cancer from different
countries (by polymerase chain reaction amplifica-
tion with species-specific primers), and considering
their proinflammatory potential, the authors sug-
gested that these three species could play roles in the
carcinogenic progress.
More recently, Blackett et al.,45 using a mixed
culture-dependent and culture-independent app-
roach, investigated the role of microbiota in the
progression of EAC through the GER–esophagitis–
intestinal metaplasia–dysplasia–adenocarcinoma
cascade and observed a significant enrichment in
Campylobacter (mostly C. concisus) in GERD and
BE, compared with controls and esophageal EAC.
On the basis of the observation that Campylobacter
spp. (mostly C. concisus) are among the Gram-
negative species consistently enriched in type II
esophageal microbiota42,43,45 and on their overall
higher prevalence in early stages of the EAC cascade
(i.e., higher prevalence in GERD–esophagitis and
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BE compared to EAC and controls),45 it has been
proposed that this pathogen could play a role in EAC
progression similar to that of Helicobacter pylori in
gastric cancer.69 C. concisus can colonize the oral
cavity and has recently been recognized as a poten-
tial human pathogen, with diverse pathotypes being
identified in addition to commensal strains.70,71
Chronic esophageal colonization by virulent C.
concisus strains, favored by the inflammation
and dysbiosis associated with GER, could induce
augmentation of the inflammatory and metaplastic
responses, favoring progression to EAC. Indeed, vir-
ulent C. concisus strains have been shown to induce
the expression of proinflammatory cytokines asso-
ciated with carcinogenesis.69 On the other hand, the
lower prevalence of this pathogen in EAC would be
consistent with the “driver–passenger” theory (i.e.,
a “driver” pathogen would be responsible for the
initial steps in carcinogenesis, in turn favoring the
proliferation of “passenger” bacteria with a com-
petitive advantage in the tumor microenvironment
and involved in disease progression)72 and would
mirror the lower prevalence of H. pylori in gastric
cancers.69
Besides the specific role of Campylobacter spp.,
the GERD-related dysbiosis, characterized by the
shift from type I to type II esophageal micro-
biota, has been suggested to contribute to EAC
development.26,28–31 In the proposed pathogenetic
scheme, a refluxated esophageal mucosa would ini-
tially favor the switch between a Gram positive–
dominated microbiota (i.e., type I microbiota)
to a Gram negative–enriched one (i.e., type II
microbiota), owing to the lower susceptibility of
many Gram-negative species to acidic pH and bile
salts. In turn, the increased abundance of Gram-
negative bacteria would induce a strong inflamma-
tory response through lipopolysaccharide (LPS, a
component of Gram-negative outer membranes)-
mediated activation of innate immunity, initiat-
ing the vicious cycle of dysbiosis–inflammation–
dysbiosis.26,28–31,60,61 Exacerbated innate immunity
signaling has been demonstrated for GERD—
esophagitis, BE, and EAC,26,28–31 and also in a recent
animal model of EAC.47 In addition, LPS has been
associated with a dose-dependent decrease of the
basal tone of the lower esophageal sphincter and
with a delay in gastric emptying, both factors con-
tributing to the maintenance and exacerbation of
GER.26,28–31
ConcerningESCC, anegative correlationbetween
esophageal microbial richness and esophageal squa-
mous dysplasia (ESD) has recently been observed
using a culture-independent approach,73 suggesting
that individuals with a lower esophageal microbial
complexity could bemore prone to develop ESD.An
additional study performed using anNGS approach
demonstrated an enrichment in Clostridiales and
Erysipelotrichales (phylumFirmicutes) in the gastric
corpus microbiota of patients affected by ESD and
ESCC compared with controls, pointing to a possi-
ble involvement of gastric dysbiosis in ESD–ESCC
progression.74 Recently, a possible role for specific
bacteria in the pathogenesis of ESCC has also been
investigated by Gao et al.,75 who focused on the
possible relationships between Porphyromonas gin-
givalis, an oral pathogen thought to be involved
in oral squamous cell carcinoma tumorigenesis,
and ESCC, given the histological similarity of the
two cancers. The authors reported that P. gingivalis
could selectively infect the cancerous and adjacent
esophageal mucosa of ESCC subjects but not the
healthy mucosa of controls. Moreover, the presence
of P. gingivalis was positively correlated with ESCC
severity (i.e., cancer cell differentiation, metastasis)
and poor prognosis (i.e., ESCC survival rate) and,
therefore, it has been suggested thatP. gingivalismay
serve as biomarker of ESCC.
Microbiota in uncommon esophageal
diseases
Two recent studies (Table 3)49,50 investigated, using
NGS approaches, the esophageal microbiota in
eosinophilic esophagitis (EoE), an allergic disease
characterized by a dense eosinophilic infiltrate
within the esophagealmucosa.76 Despite differences
in the study design and experimental procedures,
both studies identified a distinct esophageal micro-
biota in active EoE (i.e., with15 eosinophils/high-
power field) compared to controls.
Benitez et al.49 observed a shift in the relative
abundance of specific taxa in active EoE com-
pared with controls. In particular, Neisseria and
Corynebacterium were significantly more abundant
in the active EoE cohort, while Firmicutes (includ-
ing Streptococcus and Atopobium) were consistently
enriched among controls. Interestingly, no signif-
icant differences were observed between inactive
EoE (i.e., < 15 eosinophils/high-power field) and
controls, suggesting a major role of the esophageal
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inflammatory state in modulating the local micro-
biota composition. In support of this finding, the
authors also observed an increase in the relative
abundance of Granulicatella (phylum Firmicutes)
and Campylobacter (phylum Proteobacteria) fol-
lowing the reintroduction of highly allergenic foods
in EoE patients previously treated with an empiric
six food–eliminationdiet, a situation that leads to an
increased esophageal inflammatory state. Overall
concordant results, in terms of inflammation-
mediated modulation of microbiota composition,
were obtained in the study by Harris et al.,50 who
observed an enrichment in Proteobacteria (mostly
Haemophilus) and a decrease in Firmicutes in
patients with active EoE compared with inactive
EoE and controls. In the same study, a modulatory
effect of PPI treatment was also observed in a small
number of GERD patients (i.e., decrease of Firmi-
cutes and increase in Proteobacteria), which did
not confirm what was previously observed by Amir
et al.46 and points out the need to further investigate
the effects of PPIs on the esophageal microbiota.
A single study has investigated the esophageal
microbiota composition in patients affected by
chagasic megaesophagus (a sequela of Trypanosoma
cruzi infection), using a culture-dependent app-
roach (Table 3).48 In addition to a higher bacterial
load related to chronic stasis, a greater variability
and an apparent enrichment in Veillonella were
observed, compared with controls. Acknowledging
that chagasic megaesophagus represents an impor-
tant risk factor for ESCC, the authors encouraged
further studies to assess the potential role of a
procarcinogenic dysbiosis in disease progression.
Conclusions and perspectives
An increasing number of studies published dur-
ing the last decades have significantly advanced our
knowledgeon the compositionof esophagealmicro-
biota in healthy subjects (Table 1) and have under-
scored a possible role of dysbiotic conditions in the
pathogenesis of some esophageal diseases, especially
those related to GER (Tables 2 and 3). However,
experimental findings have been variable, and a cur-
rent understanding of these aspects remains limited.
Therefore, additional studies are warranted to con-
firm causative relationships between dysbiosis or
specific bacterial species andGERD-related or other
esophageal diseases and to establish the underlying
molecular mechanisms.
When planning similar studies, itmust be consid-
ered that investigation of the esophageal microbiota
in health and disease poses a number of method-
ological and technological challenges. First, obtain-
ing samples requires invasive procedures that are not
always acceptable, and taking longitudinal samples
from the same subject can be difficult or impossible.
These aspects have negatively affected the perfor-
mance of long-term longitudinal studies and lim-
ited the recruitment of large human cohorts, as
demonstrated by the limited number of enrolled
subjects in various studies (Tables 1–3). Second,
the interactions within the esophageal environment
are difficult to reproduce in vitro, which limits the
possibility of studying the esophageal ecosystem
using in vitro models,77–79 while the available ani-
mal models to study esophageal diseases (e.g., the
BE animal model based on a surgical anastomo-
sis in the rat) are complex and have several short-
comings, including species differences, the require-
ment of surgical expertise, duration, and costs.80
Third, culture-dependent methods can contribute
only partially to depicting the population structure
of the resident microbiota, since several taxa are
difficult or impossible to cultivate. In this context,
the use of culture-independent approaches, based
onmolecular analysis of metagenomic libraries, has
greatly helped in overcoming the limitations of con-
ventional culture-dependent approaches, allowing
for a higher analytical resolution and providing
for a more comprehensive picture of the micro-
bial communities associated with the esophageal
mucosa.37,39,41,43–47,49,50,59,68 However,metagenomic
data alone cannot determine whether an organism
is alive or whether only DNA traces are present.
Moreover, in culture-independent approaches, sig-
nificant biases could be introduced during the
sample-processing steps, from the DNA extraction
to the amplification and sequencing of 16S rRNA
genes, which can be responsible for artifactual diver-
sity in the microbiota composition.81 Fourth, the
study design must be carefully considered in terms
of patient characteristics, inclusion and exclusion
criteria, and sampling criteria, which can be critical
for the comparative analysis of results. The pres-
ence or absence of GERD symptoms, for exam-
ple, has been indicated among the causes respon-
sible for data discrepancies.46 Moreover, exclusion
criteria were highly heterogeneous or not always
clearly specified, particularly concerning the use
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of some drugs that can influence the composi-
tion of the microbiota (e.g., antibiotics, PPIs, non-
steroidal anti-inflammatory drugs, probiotics)82–84
(Tables 1–3). Another variable aspect related to the
use of drugs is the time between the last drug admin-
istration and endoscopy considered at risk for alter-
ations in esophageal microbiota (from a minimum
of 2 to a maximum of 8 weeks), but in fact no
information is currently available on how long the
residentmicrobiota could take to completely restore
its original composition and structure (resilience)10
within the esophagus. Another source of variability
may be the sampling methodology, which can differ
in terms of the type of sample (biopsy, brush, aspi-
rate) (Tables 1–3).Most studieshave investigated the
esophageal microbiota using tissue biopsies, which
would be the most suitable specimen, considering
the presence of a mucosal adherent microbiota at
this body site. However, sampling by brushes or
aspirates was adopted by some authors, and a less
invasive sampling method has been recently pro-
posed and used as an alternative to esophageal
biopsies.39,50 However, despite the choice of the
sampling method, esophageal biopsies are always
necessary for a direct histological examinationof the
diseased tissues in order to avoid misclassification
and require additional invasive procedures. More-
over, taking esophageal samples is often associated
with the risk of contamination by oropharyngeal or
gastric secretions.
In this scenario, the following aspects would
seem important for future investigations: (1) enroll-
ment of larger cohorts of homogeneous categories
of subjects and inclusion of longitudinal follow-
ups; (2) expanding the studies addressed to inves-
tigate the transcriptomic and metabolomic aspects
of the esophageal microbiota; and (3) association
of microbiota investigations with immunological
investigations to clarify the potential role of micro-
bial components in induction/persistence of the
inflammatory status that characterizes the evolu-
tion of GERD to BE and EAC. In particular, it
would be important to confirmandbetter clarify the
potential role played by dysbiosis of the esophageal
microbiota or of specific pathogens in the multistep
evolution model of GERD toward EAC, which still
remains unclear.
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